Modern Healthcare5h
FDA warns Dexcom over continuous glucose monitor testing
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Medscape1d
Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
Drug Delivery Business7d
Insulet expands Omnipod 5 to more countries, prices $450M offering
Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.
MedTech Dive5d
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data
Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.
Nasdaq11d
Looking At DexCom's Recent Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ ... company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem ...
DexCom falls after warning letter from FDA related to quality concerns
DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...